
TXG Earnings
10X Genomics Inc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of 10X Genomics Inc(TXG) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of 10X Genomics Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
- | 2025-08-07 | After Hours | -0.35 | 0.28 | +180.00 | 139.44M | 172.90M | +24.00 | -3.98 | - |
FY2025Q1 | 2025-05-08 | After Hours | -0.45 | -0.28 | +37.78 | 132.51M | 154.88M | +16.88 | +1.62 | +5.68 |
FY2024Q4 | 2025-02-12 | After Hours | -0.32 | -0.40 | -25.00 | 164.98M | 165.02M | +0.02 | -0.50 | -3.67 |
FY2024Q3 | 2024-10-29 | After Hours | -0.34 | -0.30 | +11.76 | 151.67M | 151.65M | -0.01 | +4.43 | +9.82 |
FY2024Q2 | 2024-08-08 | After Hours | -0.47 | -0.32 | -31.91 | 150.05M | 153.10M | +2.03 | +4.50 | +15.81 |
FY2024Q1 | 2024-04-30 | - | -0.46 | -0.50 | -8.70 | 142.08M | 141.01M | -0.76 | +3.10 | -4.05 |
FY2023Q4 | 2024-02-15 | - | -0.36 | -0.41 | -13.89 | 183.74M | 183.98M | +0.13 | -0.02 | -5.24 |
FY2023Q3 | 2023-11-02 | - | -0.45 | -0.51 | -13.33 | 151.28M | 153.64M | +1.56 | +6.44 | +10.52 |
FY2023Q2 | 2023-08-03 | - | -0.39 | -0.53 | -35.90 | 140.00M | 146.82M | +4.87 | -0.36 | -10.82 |
- | 2023-05-03 | - | -0.38 | -0.44 | -15.79 | - | - | - | +4.53 | +3.04 |
TXG Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, 10X Genomics Inc reported performance for , announced on 2025-08-07. The company achieved an EPS of 0.28, compared to analyst estimates of -0.35 by 180.00% . Revenue for the quarter reached 172.90M compared to expectations of 139.44M by 24.00% .
The stock price reacted with a -3.98% one-day change and a % five-day change following the earnings release. These movements reflect market reaction in 10X Genomics Inc growth trajectory and strategic initiatives.
TXG Earnings Forecast
Looking ahead, 10X Genomics Inc(TXG) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 139.41M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been Revise Upward by 0.04%. For the upcoming , revenue estimates have been adjusted Go Up by 32.75% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in 10X Genomics Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between TXG's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Upward

+0.04%
In Past 3 Month
Stock Price
Go Up

+32.75%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:609.61M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price12.81
TXG Revenue and EPS Performance: A Historical Perspective
10X Genomics Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
(2025-08-07,After Hours):
EPS: 0.28 (Actual) vs.-0.35 (Estimate) (180.00%)
Revenue: 172.90M (Actual) vs. 139.44M (Estimate) (24.00%)
Price Reaction: -3.98%(1-Day), %(5-Day)
FY2025Q1 (2025-05-08,After Hours):
EPS: -0.28 (Actual) vs.-0.45 (Estimate) (37.78%)
Revenue: 154.88M (Actual) vs. 132.51M (Estimate) (16.88%)
Price Reaction: 1.62%(1-Day), 5.68%(5-Day)
FY2024Q4 (2025-02-12,After Hours):
EPS: -0.40 (Actual) vs.-0.32 (Estimate) (-25.00%)
Revenue: 165.02M (Actual) vs. 164.98M (Estimate) (0.02%)
Price Reaction: -0.50%(1-Day), -3.67%(5-Day)
Earnings Reaction
The chart below shows how TXG performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TXG sees a +3.64% change in stock price 10 days leading up to the earnings, and a -2.69% change 10 days following the report. On the earnings day itself, the stock moves by +2.76%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -3.98% on the day following the earnings release and then changed by 0.08% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
10X Genomics Inc (TXG) Q2 2025 Earnings Call Summary
Neutral
2025-08-09
The earnings call presented mixed signals. Strong financial metrics, such as improved gross margins and a shift from loss to net income, were overshadowed by the withdrawal of revenue guidance and ongoing macroeconomic challenges impacting customer spending. The Q&A revealed cautious optimism but highlighted uncertainties in funding and spending, particularly in the academic sector. The Scale acquisition and product roadmap offer potential, but immediate impact is limited. The market cap suggests moderate stock movement, leading to a neutral prediction.
10X Genomics Inc (TXG) Q1 2025 Earnings Call Summary
Negative
2025-05-08
The earnings call reveals a mixed financial performance with declining instrument revenue and flat guidance. The Q&A highlights concerns about funding uncertainties and declining CapEx, particularly in academia and government sectors. While gross margins improved, the lack of a share repurchase program and weak guidance with possible headcount reductions point to ongoing challenges. The market cap suggests a moderate reaction, resulting in a negative sentiment prediction of -2% to -8% over the next two weeks.
10X Genomics Inc (TXG) Q4 2024 Earnings Call Summary
Negative
2025-02-12
The earnings call presents a mixed but overall negative outlook. Revenue declines in key segments and flat guidance, coupled with uncertainties around NIH funding cuts, suggest challenges ahead. Despite some positive aspects like improved gross margins and cost management, the lack of a shareholder return plan and unclear management responses in the Q&A raise concerns. The market cap indicates moderate sensitivity, but the negative elements outweigh positives, leading to a predicted stock price decline.
10x Genomics, Inc. (TXG) Q3 2024 Earnings Call Summary
Neutral
2024-10-30
The earnings call reveals mixed signals. Financial performance shows a slight revenue decline, but improved gross profit and margin. The Q&A highlights challenges like macro environment impacts and sales force issues, with management's responses lacking clarity on resolution timelines. The absence of a share repurchase program and no strong positive catalysts like new partnerships or guidance raises further concerns. Given the market cap and these mixed elements, the stock is likely to remain stable, resulting in a neutral prediction.
People Also Watch

NEO
Neogenomics Inc
6.080
USD
+4.47%

IOVA
Iovance Biotherapeutics Inc
2.230
USD
+13.20%

PRDO
Perdoceo Education Corp
31.970
USD
+3.43%

SKWD
Skyward Specialty Insurance Group Inc
49.260
USD
+0.72%

WWW
Wolverine World Wide Inc
27.690
USD
+3.51%

CDLR
Cadeler A/S
20.140
USD
+0.90%

GLP
Global Partners LP
49.850
USD
+1.73%

FINV
FinVolution Group
9.110
USD
+1.67%

FBNC
First Bancorp (North Carolina)
51.820
USD
+5.48%

STC
Stewart Information Services Corp
70.100
USD
+3.18%
FAQ

What were the key highlights of TXG’s latest earnings report for ?
TXG reported its earnings on 2025-08-07, showcasing a revenue of 172.90M against an estimate of 139.44M, resulting in a 24% surprise. The EPS was 0.28, surpassing the expected -0.35 by 180% . The stock experienced a -3.98% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

How did TXG’s stock price react after the earnings release?

What are the revenue and EPS estimates for TXG for 2025/Q2?

How does TXG’s stock price correlate with earnings forecast revisions?

What should investors expect from TXG’s next earnings report?
